Latest developments in high content screening systems.

By Dr John Comley
High-content screening (HCS) is a well-established approach for the multiparametric analysis of cellular events. Since its first introduction more than a decade ago, HCS imaging systems h...

Phenotypic Drug Discovery: striving towards the highest level of biological relevance.

By Dr John Comley
Winter 2015/16
Phenotypic drug discovery (PDD) implies screening where the molecular mechanism of action is not assumed and does not require knowledge of the molecular target.

High Throughput Flow: a high content platform for phenotypic screening?

Dr John Comley
Spring 2015
Flow cytometry has many of the technology attributes (eg multi-parameter analysis of cell suspensions) needed when attempting to profile a phenotypic drug response. However, for flow cyto...

Redesigning therapeutic drug monitoring for the 21st century.

By Lewis Couchman
Winter 2014
Therapeutic drug monitoring services are a vital part of the pathology laboratory’s remit, providing essential clinical information to guide the management and treatment of a wide range...

Immunoassay Automation: hands-free platforms set to change the workflow in research labs.

By Dr John Comley
Winter 2014
The automation of immunoassays is not a new trend, but one that has already witnessed decades of innovation in diagnostic laboratories. However, in terms of hands-free automated processin...

Opportunities for phenotypic screening in drug discovery.

By David C. Swinney
Fall 14
Renewed awareness of the value of phenotypic screening to drug discovery1-5 creates many new opportunities to increase drug discovery success and productivity. These opportunities include...

Industrial-scale screening accelerates discovery of novel drug combination therapies.

By Dr Oliver Leven and Dr Eric Tang
Fall 14
Drug combination therapies are widely recognised as essential therapeutic treatments for chronic conditions ranging from infectious diseases to cancer and HIV/AIDS. Such therapies can enh...

The current status of non-biopharma drug discovery.

By Dr John Comley
Spring 2014
Screening centres in academic institutions and non-profit organisations have, over the past decade, become an established mechanism to exploit novel targets and neglected diseases and to ...

Fluorescence Lifetime Assays.

By Dr Graham Cotton, Dr Wayne Bowen, Dr Robert Grundy and Dr Ulrich Hassiepen
Fall 13
The benefits of fluorescence lifetime (FLT)-based technologies have been
highlighted for more than a decade but thus far they have failed to gain
widespread acceptance. Significant ...

Outsourced Kinase Profiling Services: adding value to in-house kinase programmes.

Dr John Comley
Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry. The importance of this activ...

A decade of RNAi screening: too much hay and very few needles.

By Bhavneet Bhinder and Dr Hakim Djaballah
Summer 2013
RNAi screening is arguably the fastest growing field with the premise to better understand gene function at the genome level. It has been hailed as the second genomics wave, and in combin...

Adoption of high content screening at HTS laboratories.

By William Downey and Dr Jennifer Hartigan
Spring 2013
Over the past five years, a majority of HTS laboratories have adopted high content screening (HCS) in their operations. As HTS laboratories have sought more biologically-relevant assays, ...

Fragment library design the evolution of fragmentbased lead discovery.

By Dr Edward Zartler, Dr Chris Swain and Simon Pearce
Winter 2012/13
With the growing need to streamline the drug discovery process, screening against fragment libraries rather than drug-like molecules has become increasingly adopted as an integral part of...

Changing dynamics in dispense and imaging assays. Summer 2006

By Dr John Comley
Summer 2006
The prospects for a significant shift in dispense and imaging (D&I) assays towards a greater utilisation of calcium-mediated flash luminescence readoutsappears to be finally under way. Dr...

Miniaturisation of assay development and screening. Summer 2006

By Andreas Boettcher and Dr Lorenz M. Mayr
Summer 2006
In recent years we have seen a strong increase in the number of chemical compounds and molecular targets used for lead discovery by high-throughput screening among most Pharma and Biotech...

Convfocal widefield high content imaging. Fall 06

By Dr John Comley
Fall 2006
A variety of new confocal hardware and software solutions have recently become available to support high content imaging. Most of the solutions have in common the potential of rejecting o...